

## Results of 2024 Annual General Meeting

**Melbourne, Australia; 26 November 2024: Starpharma (ASX: SPL, US OTC: SPHRY), announces the details of the resolution and the proxies and votes received in respect of resolutions 2 to 4 at its Annual General Meeting (AGM) held today in accordance with ASX listing rule 3.13.2 and section 251AA of the Corporations Act, as set out in the attached proxy and voting summary.**

As noted in the AGM, the Chair has exercised discretion to adjourn one item of business until Friday 29 November 2024, being the vote on the Resolution 1 - Adoption of the Remuneration Report. This is the result of an offshore custodian needing additional time to amend votes on behalf of beneficial owners.

Details of the adjourned meeting and voting instructions on Resolution 1 will be released on the ASX market announcements platform once arrangements are made to reconvene the meeting for Resolution 1.

---

### About Starpharma

Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit [www.starpharma.com](http://www.starpharma.com) or connect with Starpharma on [LinkedIn](https://www.linkedin.com/company/starpharma).

---

### WE Communications

Hannah Howlett  
+61 450 648 064  
[WF-AUStarPharma@we-worldwide.com](mailto:WF-AUStarPharma@we-worldwide.com)

### Starpharma Holdings Limited

Cheryl Maley, Chief Executive Officer  
Justin Cahill, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

### Disclosure

This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

### Forward-Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	Resolution has been postponed to the adjourned meeting.				Resolution has been postponed to the adjourned meeting.			Adjourned
2 Re-election of Board endorsed Director, Ms Lynda Cheng	Ordinary	134,007,086 67.57%	63,595,881 32.07%	710,114 0.36%	295,143	136,274,058 67.89%	64,455,405 32.11%	896,837	Carried
3 Approval of issue of Performance Rights to Ms Cheryl Maley	Ordinary	168,804,658 90.94%	16,090,364 8.67%	731,114 0.39%	516,406	171,323,724 91.30%	16,326,326 8.70%	963,700	Carried
4 Re-insertion of proportional takeover approval provisions in the Constitution	Special	195,526,623 99.16%	903,763 0.46%	731,114 0.38%	1,446,724	199,182,803 99.50%	996,773 0.50%	1,446,724	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

**Resolution(s) proposed but not put to the meeting**

Resolution	Reason for not putting the resolution to the meeting
1 Adoption of Remuneration Report	Resolution was not put to the meeting as it has been postponed to the adjourned meeting.